Hack My Net Worth: How Can I Boost My Assets by $40,000?
When Money Gets in the Way of Major Life Decisions
The Right Ways to Split the Bill at a Restaurant
Week's Winners and Losers: Hasbro Plays, Disney World Fades
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.